Qanat Pharma

Qanat Pharma is an early-stage biotechnology company specialized in the field of targeted protein degradation (TPD). The company focuses on the discovery and development of novel, orally available small molecules, specifically E3 ligase ligands, to create next-generation molecular glues and PROTACs (Proteolysis Targeting Chimeras). By leveraging its proprietary platform to identify unique E3 ligase binders, Qanat Pharma aims to address previously 'undruggable' targets in oncology and immunology. The company's approach seeks to expand the repertoire of E3 ligases beyond the commonly used Cereblon and VHL to improve tissue specificity and therapeutic efficacy.